Challenges for the development of vaccines against Haemophilus influenzae and Neisseria meningitidis.
The development of protein-polysaccharide conjugate vaccines has had a major impact on Haemophilus influenzae type b disease. The application of this technology to Neisseria meningitidis is also striking, particularly for serogroup C. However, significant challenges exist for the development of vaccines against non-typeable H. influenzae and against N. meningitidis serogroup B. Issues such as non-vaccine-strain replacement and correlates of protection need to be addressed as well as the longer-term implications of vaccination against what are essentially 'normal' microflora.
Cripps
Allan W
AW
Gadi Research Centre for Health and Medical Sciences, University of Canberra, ACT 2601, Australia. allan.cripes@canberra.edu.au
Foxwell
Ruth
R
Kyd
Jennelle
J
D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D016667:Bacterial Capsules; D001428:Bacterial Vaccines / Q000276:immunology*; D018073:Haemophilus Vaccines / Q000276:immunology*; D006801:Humans; D009345:Neisseria meningitidis / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D011135:Polysaccharides, Bacterial